Roth Capital keeps a Buy rating and $209 price target on Constellation Brands (STZ) after its Q4 results and outlook. The company’s initial 2027 guidance was below consensus but this outlook should not be relied upon as the firm expects fundamentals to accelerate and the management’s ranges to prove “unnecessarily low” rather than conservative. With the World Cup, tax refunds, a ban on intoxicating hemp, and lapping disruptions to Hispanic consumer habits, Constellation Brands Beer depletions should improve, outpace guidance, and justify a re-rating, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STZ:
- Closing Bell Movers: STAAR Surgical up nearly 20% on pre-announcement
- STZ Earnings: Constellation Brands Slips as Changing Consumer Trends Remain a Challenge
- Constellation Brands Reports Fiscal 2026 Results, Raises Dividend
- Constellation Brands sees comparable FY27 EPS $11.20-$11.90, consensus $12.36
- Constellation Brands down 2% at $147.22 after Q4 results and FY27 guidance
